Philippe E. Spiess

Jul 24, 2024 | digitalcommons.library.tmc.edu | Andrea Necchi |Philippe E. Spiess |Roger Li |Petros Grivas

IMPORTANCE: Tumor mutational burden (TMB) is a putative biomarker of efficacy for immune checkpoint inhibitor (ICI) therapies of solid tumors, but not specifically for penile squamous cell carcinoma (PSCC). OBJECTIVE: To characterize biomarker features and ICI therapy outcomes associated with high TMB in PSCC in the routine clinical practice setting.

May 14, 2024 | europeanurology.com | Andrea Necchi |Philippe E. Spiess

1 Costa de Padua T. Sabino Marques Monteiro F. Necchi A. Spiess P.E. Redefining rare genitourinary cancers: an initiative led by the Global Society of Rare Genitourinary Tumors. Eur Urol. 85: 414-416 ]. This is partly because the translation of molecular and immune research knowledge to improvements in prognostication, novel therapies, and better patient outcomes has been very challenging. Nevertheless, research efforts in PSCC have led to significant milestones over the past 5 yr.

Apr 15, 2024 | nature.com | Giuseppe Basile |Andrea Necchi |Philippe E. Spiess

Centralization of care for penile cancer has been underscored in the 2023 updated EAU–ASCO guidelines. Expertise consolidation enhances patient care, addressing penile cancer complexities from diagnosis to treatment. Centralization initiatives, like the European Reference Networks, and dedicated scientific societies have crucial roles in guiding centralized care pathways to ultimately improve patient outcomes.

Feb 24, 2024 | europeanurology.com | Porto Alegre |Andrea Necchi |Philippe E. Spiess

Reply to Behnam Shakiba’s Letter to the Editor re: Emilien Seizilles de Mazancourt, Juliette Cotte, Caroline Plassais, et al. Sexual and Moral Harassment of French Urologists in Training and Barriers to Reporting: Results from a National Survey. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.10.020

Feb 24, 2024 | europeanurology.com | Porto Alegre |Andrea Necchi |Philippe E. Spiess

Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer